DSS (DSS) Q3 2024 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2024 earnings summary
13 Jun, 2025Executive summary
DSS, Inc. operates nine business lines across five segments: Product Packaging, Biotechnology, Direct Marketing, Commercial Lending, and Securities & Investment Management, with discontinued operations in Digital Transformation, Secure Living, and Alternative Energy.
For the quarter ended September 30, 2024, total revenue increased 34% year-over-year to $5.6 million, driven by higher printed product and rental income, but decreased 28% to $13.7 million for the nine months due to declines in rental and direct marketing revenues.
Net loss attributable to common stockholders was $5.3 million for the quarter and $14.0 million for the nine months, both improved from prior year periods.
The company completed the deconsolidation of Sharing Services Global Corporation (SHRG) in May 2023, impacting the Direct Marketing segment and resulting in discontinued operations.
Financial highlights
Q3 2024 revenue rose 34% year-over-year to $5.6 million; nine-month revenue fell 28% to $13.7 million.
Net loss for Q3 2024 was $5.3 million, an improvement from $4.3 million loss in Q3 2023; nine-month net loss was $14.0 million, improved from $30.3 million loss in 2023.
Gross margin for the nine months was negative, with operating loss of $14.3 million, improved from $15.6 million loss year-over-year.
Cash and cash equivalents increased to $11.6 million as of September 30, 2024, from $6.6 million at year-end 2023.
Net cash used in operating activities was $9.2 million for the nine months, down from $21.0 million in the prior year.
Outlook and guidance
Management believes current cash and marketable securities, along with planned asset sales and cost reductions, are sufficient to fund operations for at least the next 12 months.
The company expects improved future cash flows due to the deconsolidation of loss-generating subsidiaries and ongoing expense reductions.
Latest events from DSS
- $10M shelf registration supports a multi-division growth strategy and future public offerings.DSS
Registration Filing16 Dec 2025 - Diversified issuer seeks $10M via shelf registration to fund growth across multiple business lines.DSS
Registration Filing16 Dec 2025 - Shareholders will elect directors, ratify the auditor, and vote on executive pay, with major ownership concentrated.DSS
Proxy Filing2 Dec 2025 - Proxy covers director elections, auditor ratification, and executive pay, with strong board oversight.DSS
Proxy Filing2 Dec 2025 - Proxy covers director elections, auditor ratification, compensation, and major shareholder control.DSS
Proxy Filing2 Dec 2025 - Revenue up 22% year-over-year, net loss narrows, but going concern risk persists.DSS
Q3 202514 Nov 2025 - Revenue up 27% and net loss narrowed, but going concern risk persists.DSS
Q2 202514 Aug 2025 - Revenue and net loss improved sequentially as cost cuts and asset sales offset segment declines.DSS
Q2 202413 Jun 2025 - DSS, Inc. posted a $46.9M net loss in 2024, but completed the Impact BioMedical IPO.DSS
Q4 20249 Jun 2025